DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Green Mining - BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous/Sustainability B.R.A.I.N. Biotechnology Research And Information Network AG: Green Mining - BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores 20.06.2018 / 08:29 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Green Mining BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores * Industrially relevant production of precious metals realized on the metric ton scale, even after scale-up of bio-based method * Precious-metal enrichment using microorganisms from the BRAIN BioArchives * Expansion of the CyPlus product portfolio for Green Mining * Market launch of initial products expected in the course of 2019 The bioeconomy company BRAIN AG and CyPlus GmbH have announced the development of an initial range of market-relevant products for the global mining industry. This work has been carried out as part of a multi-year collaboration between the companies in the area of biological ore processing to extract gold and silver. On the basis of successful laboratory research up to the 100-liter scale, the partners then succeeded in scaling up the process to the metric ton level last October, thus reaching an important milestone in the last stage towards market maturity. The bio-based process could produce the desired precious metals from ores in industrially relevant yields, even for throughputs on the metric ton scale. The method is now being further improved for industrial application and this process is sufficiently advanced for the partners to expect the market launch of the first range of products as early as 2019. The extraction of precious metals from the ores is based on the use of naturally occurring and enhanced microorganisms from the BRAIN BioArchives. During the ongoing collaboration, the partners very soon reached the goal of identifying a variety of microorganisms that, having highly specific adhesion effects, give the gold and silver-bearing minerals a new physical property. This effect can be exploited to separate gold or silver specifically from gangue and enrich it in an integrated process step. "Our research aims at developing bio-based methods that could offer innovative and sustainable processes for green mining in global markets for ore processing," says Stefan Welbers, Senior Vice President and General Manager of CyPlus GmbH. "For this reason we've continuously kept the technical requirements and structural conditions in mines in mind. In the foreseeable future, for example, we'll be able to offer mine operators the possibility of integrating advanced biotechnological methods into their current processes without significant investment costs or delays in operation. In this way, we're expanding our technology portfolio to include biological components for efficient and eco-friendly processing of precious metals." Dr. Guido Meurer, member of the Management Board and Unit Head Producer Strain Development at BRAIN AG, says: "We're delighted - and proud - that the BRAIN and CyPlus interdisciplinary team has succeeded in establishing a groundbreaking biological process for a new processing technology and developing it to high product maturity in just a few years. With our processes for Green Mining it will be possible in the future to exploit ore deposits containing precious metals even in regions where the conventional processes are out of the question. Green Mining is an increasingly important issue and an attractive field of business also in view of the increasing scarcity of raw materials." The partners have already filed a patent for the bio-based method, which describes the special microorganisms possessing selectively adhesive properties that can be used to enrich precious metals from ores. Under the mining program, BRAIN is also researching into biological solutions for what is known as Urban Mining, where precious metals are obtained from side streams and waste streams such as slags, ashes, and electronic scrap. The BRAIN BioXtractor (see www.brain-biotech.de/en/bioxtractor) has been established as a demo system for this purpose. About BRAIN B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience segment comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en. About CyPlus CyPlus is a globally established company in cyanides. The Evonik subsidiary provides innovative products, technologies and services to customers in the mining, chemical, pharmaceutical, and surface treatment industries. The company meets the extensive and strict requirements of the international mining industry as a supplier of cyanides in accordance with the provisions of the "International Cyanide Management Code" (ICMC). Production sites in Europe as well as sales and distribution offices on all continents provide customers swift and reliable service. CyPlus regards itself as a pacesetter of progress and sustainability. Further information is available at www.cyplus.com. BžRžAžIžN Biotechnology Research And Information Network AG Darmstädter Str. 34-36 64673 Zwingenberg, Germany www.brain-biotech.de/en Media Contact Thomas Deichmann Head of Public Relations Tel.: +49-(0)-6251-9331-72 E-Mail: td@brain-biotech.de Investor Relations Contact Dr. Martin Langer Executive Vice President Corporate Development Tel.: +49-(0)-6251-9331-16 E-Mail: ir@brain-biotech.de CyPlus GmbH Rodenbacher Chaussee 4 63457 Hanau-Wolfgang, Germany www.cyplus.com Contact Frank Ladwig Marketing Manager Technologies & Services Tel.: +49-6181-59-6944 E-Mail: frank.ladwig@cyplus.com Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements. --------------------------------------------------------------------------- 20.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: ir@brain-biotech.de Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 696921 20.06.2018

Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 8,76 10,37 21,13 22,79 24,11 27,05 38,56 43,00
EBITDA1,2 -3,72 -3,81 -3,10 -12,36 -7,70 -6,55 -2,47 -0,50
EBITDA-Marge3 -42,47 -36,74 -14,67 -54,23 -31,94 -24,21 -6,41 -1,16
EBIT1,4 -4,39 -4,82 -4,57 -13,81 -9,37 -9,57 -7,17 -3,70
EBIT-Marge5 -50,11 -46,48 -21,63 -60,60 -38,86 -35,38 -18,59 -8,60
Jahresüberschuss1 0,00 -4,52 -5,47 -14,43 -9,40 -8,37 -10,49 -4,90
Netto-Marge6 0,00 -43,59 -25,89 -63,32 -38,99 -30,94 -27,20 -11,40
Cashflow1,7 -4,85 -3,90 -4,11 -8,68 -5,80 -5,42 -3,38 -1,10
Ergebnis je Aktie8 -0,28 -0,33 -0.36 -0,97 -0,58 -0,45 -0,58 -0,27
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotechology
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 8,900 160,70
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 17,17 0,000 -18,66
13,14 - 4,17 -72,172
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 05.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2020 29.05.2020 31.08.2020 14.01.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
13,58% -5,55% -17,59% -12,06%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN